Publications by authors named "Sophie Le"
A clinical need exists for more effective intravitreal (IVT) drug delivery systems (DDS). This study tested the hypothesis that a novel biodegradable, injectable microsphere-hydrogel drug delivery system loaded with aflibercept (aflibercept-DDS) would exhibit long-term safety and biocompatibility in a non-human primate (NHP) model. We generated aflibercept-loaded poly (lactic-co-glycolic acid) microparticles with a modified double emulsion technique then embedded them into a biodegradable, thermo-responsive poly (ethylene glycol)-co-(L-lactic-acid) diacrylate/N-isopropylacrylamide hydrogel.
View Article and Find Full Text PDFMeibomian gland lipid alterations and ocular surface sequela in Awat2 knockout murine model of meibomian gland dysfunction and evaporative dry eye disease.
Ocul Surf
October 2024
Article Synopsis
- There is a need for better animal models to study meibomian gland dysfunction (MGD) and evaporative dry eye disease (EDED), leading researchers to evaluate Awat2 knockout (KO) mice for this purpose.
- The study involved various tests on both wildtype and Awat2 KO mice, including ocular examinations, lipid analysis, and gene expression assessments.
- Results showed that Awat2 KO mice exhibited characteristics similar to human MGD and EDED, such as corneal issues and impaired meibum secretion, making them suitable for testing new treatments.
CRISPR-based genome editing enables permanent suppression of angiogenic factors such as vascular endothelial growth factor (VEGF) as a potential treatment for choroidal neovascularization (CNV)-a major cause of blindness in age-related macular degeneration. We previously designed adeno-associated viral (AAV) vectors with S. pyogenes Cas 9 (SpCas9) and guide RNAs (gRNAs) to target conserved sequences in VEGFA across mouse, rhesus macaque, and human, with successful suppression of VEGF and laser-induced CNV in mice.
View Article and Find Full Text PDFThis study evaluated the tolerability and efficacy of the topical rho-kinase inhibitor netarsudil for canine primary corneal endothelial degeneration (PCED). Twenty-six eyes of 21 client-owned dogs with PCED were enrolled in a prospective, randomized, vehicle control clinical trial and received topical netarsudil 0.02% (Rhopressa®) or vehicle control twice daily (BID) for the first 4 months.
View Article and Find Full Text PDFA cross-sectional study was carried out to identify risk factors for Salmonella spp. contamination in French laying hen flocks at the end of the laying period. Five hundred and nineteen flocks were studied between October 2004 and September 2005.
View Article and Find Full Text PDF